Familial hypertrophic (FHC) and dilated cardiomyopathy (DCM) are distinct forms of cardiac hypertrophy that progress to heart failure. FHC is characterized by a thick, hypercontractile left ventricule, whereas DCM patients have thin and hypocontractile ventricles. Both FHC and DCM can result from genetic mutations to either cardiac myosin or actin. Thus, both FHC and DCM can be classified as diseases of the sarcomere, the most basic contractile unit of muscle. In the sarcomere, myosin, a molecular motor, interacts with actin to generate the power of the heart. This Program Project (3 Projects and 3 cores) focuses on mutations to myosin and actin. Using state-of-the-art techniques, we will characterize both FHC and DCM from the mechanics of the whole heart down to the molecular mechanics of a single contractile protein, to assess how structural alterations to these proteins affect the mechanical properties of the sarcomere, the muscle fiber, and the whole heart. Project 1 will use the laser trap to assess the force and motion generation of these mutants at the single molecule level. Project 2 will biochemically and structurally characterize these proteins, while Project 3 will study the mechanical properties of skinned muscle fibers and myofibrils from trans-genic mouse hearts with mutations in either myosin or actin. Project 2 will genetically engineer FHC and DCM muta-tions into myosin and actin using in vitro expression systems. The Technologies for Experimentation, Modeling and Analysis Core (Core B) will support the projects in their data collection, analysis, modeling, and biological preparation development. The Mouse Production and Ventricular Function Core (Core C) will generate mice with FHC and DCM mutant hearts to be studied at all anatomical levels by the various projects. This Core will also characterize the in vivo and in vitro ventricular performance of the transgenic hearts over time as the disease phenotype develops. The long term goals are: 1) to utilize FHC and DCM-related point mutations as a means of identifying key structural domains within the mutant sarcomeric proteins and to determine how these domains relate to the protein's molecular function; 2) to understand how point mutations in contractile proteins alter sarcomere and cardiac function so that two drastically different cardiac hypertrophies, i.e. FHC and DCM, develop.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL059408-06A1
Application #
6851581
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Varghese, Jamie
Project Start
2000-02-01
Project End
2009-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
6
Fiscal Year
2005
Total Cost
$1,990,786
Indirect Cost
Name
University of Vermont & St Agric College
Department
Physiology
Type
Schools of Medicine
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
05405
Singh, Sonia R; Robbins, Jeffrey (2018) Desmin and Cardiac Disease: An Unfolding Story. Circ Res 122:1324-1326
Lin, Brian Leei; Li, Amy; Mun, Ji Young et al. (2018) Skeletal myosin binding protein-C isoforms regulate thin filament activity in a Ca2+-dependent manner. Sci Rep 8:2604
Kensler, Robert W; Craig, Roger; Moss, Richard L (2017) Phosphorylation of cardiac myosin binding protein C releases myosin heads from the surface of cardiac thick filaments. Proc Natl Acad Sci U S A 114:E1355-E1364
McLendon, Patrick M; Davis, Gregory; Gulick, James et al. (2017) An Unbiased High-Throughput Screen to Identify Novel Effectors That Impact on Cardiomyocyte Aggregate Levels. Circ Res 121:604-616
Bhuiyan, Md Shenuarin; McLendon, Patrick; James, Jeanne et al. (2016) In vivo definition of cardiac myosin-binding protein C's critical interactions with myosin. Pflugers Arch 468:1685-95
Gupta, Manish K; McLendon, Patrick M; Gulick, James et al. (2016) UBC9-Mediated Sumoylation Favorably Impacts Cardiac Function in Compromised Hearts. Circ Res 118:1894-905
Warshaw, David M (2016) HEART DISEASE. Throttling back the heart's molecular motor. Science 351:556-7
James, Jeanne; Robbins, Jeffrey (2016) Healing a Heart Through Genetic Intervention. Circ Res 118:920-2
Mun, Ji Young; Kensler, Robert W; Harris, Samantha P et al. (2016) The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position. J Mol Cell Cardiol 91:141-7
Previs, Michael J; Mun, Ji Young; Michalek, Arthur J et al. (2016) Phosphorylation and calcium antagonistically tune myosin-binding protein C's structure and function. Proc Natl Acad Sci U S A 113:3239-44

Showing the most recent 10 out of 168 publications